In a land­mark first glimpse of hu­man da­ta from Ver­tex, CRISPR/Cas9 gene ther­a­py sig­nals ear­ly ben­e­fit

Pre­lim­i­nary da­ta on two pa­tients with blood dis­or­ders that have been ad­min­is­tered with Ver­tex and part­ner CRISPR Ther­a­peu­tics’ gene-edit­ing ther­a­py sug­gest the tech­nol­o­gy is safe and ef­fec­tive, mark­ing the first in­stance of the ben­e­fit of the use of CRISPR/Cas9 tech­nol­o­gy in hu­mans suf­fer­ing from dis­ease.

Pa­tients in these phase I/II stud­ies give up pe­riph­er­al blood from which hematopoi­et­ic stem and prog­en­i­tor cells are iso­lat­ed. The cells are tin­kered with us­ing CRISPR/Cas9 tech­nol­o­gy, and the edit­ed cells — CTX001 — are in­fused back in­to the pa­tient via a stem cell trans­plant. The ob­jec­tive of CTX001 is to fix the er­rant he­mo­glo­bin gene in patents with two blood dis­or­ders: be­ta-tha­lassemia and sick­le cell dis­ease, by un­leash­ing the pro­duc­tion of fe­tal he­mo­glo­bin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER